Relative Bioavailability Risk Assessment: A Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (1) , 8-17
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and AcyclovirJournal of Pharmaceutical Sciences, 2016
- Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [13C8]‐evacetrapib as a tracerJournal of Labelled Compounds and Radiopharmaceuticals, 2015
- Leveraging BCS in Development: A Case StudyMolecular Pharmaceutics, 2015
- Effect of Excipients on the Particle Size of Precipitated Pioglitazone in the Gastrointestinal Tract: Impact on BioequivalenceThe AAPS Journal, 2014
- Effect of Surfactants, Gastric Emptying, and Dosage Form on Supersaturation of Dipyridamole in an in Vitro Model Simulating the Stomach and DuodenumMolecular Pharmaceutics, 2014
- In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model CompoundThe AAPS Journal, 2013
- Impact of Biopharmaceutics Classification System-Based BiowaiversMolecular Pharmaceutics, 2010
- Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum modelJournal of Pharmaceutical Sciences, 2006
- Biopharmaceutics Classification System: The Scientific Basis for Biowaiver ExtensionsPharmaceutical Research, 2002
- Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrateInternational Journal of Pharmaceutics, 2000